GlassScriptPhysician profile
Tara Helfrich
NPI 1568849818
$5,280.29
in general payments reported to CMS, 2019-2025
26 companies · $2,656 in 2025
The $2,656 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $386 · 2022: $451 · 2023: $796 · 2024: $992 · 2025: $2,656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,405 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,404.87 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,076.42 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $737.17 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $524.61 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $481.57 | 2021-2025 | |
| Novo Nordisk INC | $466.01 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $426.65 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $332.76 | 2024-2025 | Auvelity, Symbravo |
| Abbott Laboratories | $184.41 | 2023-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $142.62 | 2021-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.02 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $116.08 | 2021 | |
| Astellas Pharma US INC | $107.07 | 2023-2025 | Veozah |
| Insulet Corporation | $82.66 | 2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.34 | 2025 | Caplyta |
| Dexcom, INC. | $75.50 | 2021-2024 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.46 | 2021-2024 | Xifaxan |
| Amgen INC. | $54.44 | 2024-2025 | Repatha, Repatha, Otezla |
| Lundbeck LLC | $38.54 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $33.37 | 2022-2025 | Zoryve |
| Amarin Pharma, INC. | $30.27 | 2021 | |
| Itamar Medical INC | $27.40 | 2025 | Watchpatone |
| Sanofi Pasteur INC. | $23.48 | 2023 | |
| Glaxosmithkline, LLC. | $15.19 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.25 | 2025 | |
| Electromed, INC. | $11.73 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Helfrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.